| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Behavioural artificial intelligence technology for COVID-19 intensivist triage decisions: making the implicit explicit
|
de Metz, Jesse
|
|
|
47 |
11 |
p. 1327-1328
|
artikel
|
| 2 |
COVID-19-associated invasive pulmonary aspergillosis: high incidence or difficult diagnosis?
|
Rouzé, Anahita
|
|
|
47 |
11 |
p. 1337-1338
|
artikel
|
| 3 |
COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges
|
Prattes, Juergen
|
|
|
47 |
11 |
p. 1339-1340
|
artikel
|
| 4 |
Critical influenza and prophylactic antifungal therapy for aspergillosis: a nuanced approach to a pertinent infectious disease
|
Vanderbeke, Lore
|
|
|
47 |
11 |
p. 1343-1344
|
artikel
|
| 5 |
Cytokine adsorption in severe, refractory septic shock
|
Wendel Garcia, Pedro David
|
|
|
47 |
11 |
p. 1334-1336
|
artikel
|
| 6 |
Diagnosis of spontaneous intestinal perforation using point of care ultrasound
|
Oulego-Erroz, Ignacio
|
|
|
47 |
11 |
p. 1326
|
artikel
|
| 7 |
Effect of oral chlorhexidine de-adoption and implementation of an oral care bundle on mortality for mechanically ventilated patients in the intensive care unit (CHORAL): a multi-center stepped wedge cluster-randomized controlled trial
|
Dale, Craig M.
|
|
|
47 |
11 |
p. 1295-1302
|
artikel
|
| 8 |
Fluid management in diabetic ketoacidosis: new tricks for old dogs?
|
Besen, Bruno Adler Maccagnan Pinheiro
|
|
|
47 |
11 |
p. 1312-1314
|
artikel
|
| 9 |
High dose coupled plasma filtration and adsorption in septic shock patients. Results of the COMPACT-2: a multicentre, adaptive, randomised clinical trial
|
Garbero, Elena
|
|
|
47 |
11 |
p. 1303-1311
|
artikel
|
| 10 |
Individualised versus conventional glucose control in critically-ill patients: the CONTROLING study—a randomized clinical trial
|
Bohé, Julien
|
|
|
47 |
11 |
p. 1271-1283
|
artikel
|
| 11 |
Influenza and prophylactic antifungal therapy for aspergillosis: addressing some questions first
|
Coste, Anne
|
|
|
47 |
11 |
p. 1341-1342
|
artikel
|
| 12 |
No clinically relevant removal of meropenem by cytokine adsorber CytoSorb® in critically ill patients with sepsis or septic shock
|
Liebchen, Uwe
|
|
|
47 |
11 |
p. 1332-1333
|
artikel
|
| 13 |
Post-mortem dissection of COVID-19: a pathogenic role for macrophages?
|
Velu, Prasad P.
|
|
|
47 |
11 |
p. 1322-1325
|
artikel
|
| 14 |
Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial
|
Laterre, Pierre-François
|
|
|
47 |
11 |
p. 1284-1294
|
artikel
|
| 15 |
Sodium chloride or Plasmalyte-148 evaluation in severe diabetic ketoacidosis (SCOPE-DKA): a cluster, crossover, randomized, controlled trial
|
Ramanan, Mahesh
|
|
|
47 |
11 |
p. 1248-1257
|
artikel
|
| 16 |
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
|
Evans, Laura
|
|
|
47 |
11 |
p. 1181-1247
|
artikel
|
| 17 |
The goal of personalized glucose control in the critically ill remains elusive
|
Krinsley, James S.
|
|
|
47 |
11 |
p. 1319-1321
|
artikel
|
| 18 |
The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?
|
Tatham, Kate C.
|
|
|
47 |
11 |
p. 1315-1318
|
artikel
|
| 19 |
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial
|
Rosas, Ivan O.
|
|
|
47 |
11 |
p. 1258-1270
|
artikel
|
| 20 |
Using the lung ultrasound score to monitor disease progression for COVID-19-associated ARDS
|
Nguyen, Maxime
|
|
|
47 |
11 |
p. 1329-1331
|
artikel
|
| 21 |
Would my “Eriksen” wake up again?
|
Shrestha, Gentle Sunder
|
|
|
47 |
11 |
p. 1345
|
artikel
|
Tijdschrift beschrijving